IL6 and atherosclerosis: A randomized, double-blind, phase II clinical trial demonstrated that a monoclonal antibody targeting the IL-6 receptor (ziltivekimab) significantly reduced the biomarkers of atherosclerosis-related inflammation and thrombosis formation [73], which suggests that it could be helpful to reduce the risk of cardiovascular events by inhibiting the pro-inflammatory effects of IL-6.